This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Sep 26;330(12):1138-1139.

doi: 10.1001/jama.2023.17087.

A New Dawn for Aldosterone as a Therapeutic Target in Hypertension

Bryan Williams¹

Affiliations

PMID: 37690088
DOI: 10.1001/jama.2023.17087

Editorial

A New Dawn for Aldosterone as a Therapeutic Target in Hypertension

Bryan Williams. JAMA. 2023.

. 2023 Sep 26;330(12):1138-1139.

doi: 10.1001/jama.2023.17087.

Author

Bryan Williams¹

Affiliation

¹ University College London, London, England.

PMID: 37690088
DOI: 10.1001/jama.2023.17087

No abstract available

PubMed Disclaimer

Comment on

Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.
Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, Slingsby BT, Nissen SE; Target-HTN Investigators. Laffin LJ, et al. JAMA. 2023 Sep 26;330(12):1140-1150. doi: 10.1001/jama.2023.16029. JAMA. 2023. PMID: 37690061 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information